

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
27 August 2020 (27.08.2020)



(10) International Publication Number
WO 2020/172596 A8

(51) International Patent Classification:

A61P 31/00 (2006.01) *C07K 16/28* (2006.01)

(21) International Application Number:

PCT/US2020/019319

(22) International Filing Date:

21 February 2020 (21.02.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/808,784 21 February 2019 (21.02.2019) US
62/956,871 03 January 2020 (03.01.2020) US

(71) Applicant: ELSTAR THERAPEUTICS, INC. [US/US];
840 Memorial Drive, 4th Floor, Cambridge, MA 02139
(US).

(72) Inventors: LOEW, Andreas; 840 Memorial Drive, 4th
Floor, Cambridge, MA 02139 (US). **TAN, Seng-Lai;** 840
Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).
HSU, Jonathan; 840 Memorial Drive, 4th Floor, Cam-
bridge, MA 02139 (US). **VASH, Brian, Edward;** 840
Memorial Drive, 4th Floor, Cambridge, MA 02139 (US).

(74) Agent: COLLAZO, Diana, M. et al.; Lando & Anastasi,
LLP, 60 State Street, 23rd Floor, Boston, MA 02109 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

05 November 2020 (05.11.2020)

(15) Information about Correction:

see Notice of 05 November 2020 (05.11.2020)

(54) Title: ANTI-TCR ANTIBODY MOLECULES AND USES THEREOF

(57) Abstract: The disclosure provides antibody molecules that bind to TCR V β regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating an infectious disease using the aforesaid molecules.